NasdaqGM - Delayed Quote • USD
GlycoMimetics, Inc. (GLYC)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:44 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.15 | -0.14 | -0.61 | -0.45 |
| Low Estimate | -0.15 | -0.15 | -0.68 | -0.91 |
| High Estimate | -0.14 | -0.11 | -0.56 | 0.08 |
| Year Ago EPS | -0.17 | -0.13 | -0.58 | -0.61 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 4 |
| Avg. Estimate | -- | -- | -- | 28.74M |
| Low Estimate | -- | -- | -- | 1.7M |
| High Estimate | -- | -- | -- | 56.86M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.17 | -0.18 | -0.14 | -0.15 |
| EPS Actual | -0.17 | -0.13 | -0.14 | -0.14 |
| Difference | 0 | 0.05 | 0 | 0.01 |
| Surprise % | 0.00% | 27.80% | 0.00% | 6.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.14 | -0.61 | -0.45 |
| 7 Days Ago | -0.15 | -0.14 | -0.61 | -0.45 |
| 30 Days Ago | -0.15 | -0.13 | -0.63 | -0.23 |
| 60 Days Ago | -0.15 | -0.13 | -0.63 | -0.23 |
| 90 Days Ago | -0.15 | -0.13 | -0.63 | -0.23 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 3 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GLYC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 11.80% | -- | -- | 1.60% |
| Next Qtr. | -7.70% | -- | -- | 10.50% |
| Current Year | -5.20% | -- | -- | 5.20% |
| Next Year | 26.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/27/2024 |
| Initiated | Capital One: Overweight | 12/22/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/3/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 6/15/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/4/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/30/2023 |
Related Tickers
CTMX CytomX Therapeutics, Inc.
1.6700
-3.47%
MRNS Marinus Pharmaceuticals, Inc.
1.3800
-2.13%
CGTX Cognition Therapeutics, Inc.
1.8400
0.00%
CDTX Cidara Therapeutics, Inc.
0.6810
-5.68%
PDSB PDS Biotechnology Corporation
2.6450
-8.79%
APLM Apollomics, Inc.
0.4720
-7.45%
LPTX Leap Therapeutics, Inc.
2.8000
-5.41%
ALXO ALX Oncology Holdings Inc.
15.60
-0.89%
LVTX LAVA Therapeutics N.V.
2.7100
-4.24%
VSTM Verastem, Inc.
9.84
-3.81%